{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:48:41Z","timestamp":1771868921978,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,11,21]],"date-time":"2009-11-21T00:00:00Z","timestamp":1258761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00406-009-0062-9","type":"journal-article","created":{"date-parts":[[2009,11,20]],"date-time":"2009-11-20T14:25:55Z","timestamp":1258727155000},"page":"243-248","source":"Crossref","is-referenced-by-count":7,"title":["Improved statistical analysis of moclobemide dose effects on panic disorder treatment"],"prefix":"10.1007","volume":"260","author":[{"given":"Donald C.","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald F.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. H.","family":"Uhlenhuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,21]]},"reference":[{"key":"62_CR1","first-page":"1","volume":"5","author":"M Da Prada","year":"1994","unstructured":"Da Prada M, Pieri L, Cesura AM et al (1994) The pharmacology of moclobemide. Rev Contemp Pharmacother 5:1\u201318","journal-title":"Rev Contemp Pharmacother"},{"key":"62_CR2","volume-title":"BMDP statistical software manual","author":"WJ Dixon","year":"1992","unstructured":"Dixon WJ (1992) BMDP statistical software manual. University of California Press, Berkeley"},{"key":"62_CR3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s002130050754","volume":"140","author":"J Dingemanse","year":"1998","unstructured":"Dingemanse J, Wood N, Guentert T et al (1998) Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology 140:164\u2013172","journal-title":"Psychopharmacology"},{"key":"62_CR4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02900196","volume":"247","author":"International Multicenter Clinical Trial Group","year":"1997","unstructured":"International Multicenter Clinical Trial Group (1997) Moclobemide in social phobia: a double-blind, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci 247:71\u201380","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"62_CR5","first-page":"32","volume":"141","author":"PE Keck Jr","year":"1997","unstructured":"Keck PE Jr, McElroy SL (1997) New uses for antidepressants: social phobia. J Clin Psychiatry 141:32\u201336","journal-title":"J Clin Psychiatry"},{"key":"62_CR6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/npp.1993.27","volume":"8","author":"DF Klein","year":"1993","unstructured":"Klein DF, Ross DC (1993) Reanalysis of the national institute of mental health treatment of depression collaborative research program general effectiveness report. Neuropsychopharmacology 8:241\u2013251","journal-title":"Neuropsychopharmacology"},{"key":"62_CR7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1192\/bjp.174.3.205","volume":"174","author":"B Loerch","year":"1999","unstructured":"Loerch B, Graf-Morgenstern M, Haautzinger M et al (1999) Randomized placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 174:205\u2013212","journal-title":"Br J Psychiatry"},{"key":"62_CR8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0893-133X(98)00075-X","volume":"20","author":"F Lotufo-Neto","year":"1999","unstructured":"Lotufo-Neto F, Trivedi M, Thase ME (1999) Meta-analyses of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 20:226\u2013247","journal-title":"Neuropsychopharmacology"},{"key":"62_CR9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004714-199708000-00002","volume":"17","author":"R Noyes Jr","year":"1997","unstructured":"Noyes R Jr, Moroz G, Davidson JR et al (1997) Moclobemide in social phobia: a controlled dose\u2013response trial. J Clin Psychopharmacol 17:247\u2013254","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl","key":"62_CR10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0447.1995.tb05923.x","volume":"386","author":"RG Priest","year":"1995","unstructured":"Priest RG, Gembrett R, Roberts W et al (1995) Reversible and selective inhibitors of monoamine-oxidase-A in mental and other disorders. Acta Psychiatr Scand 386(Suppl):40\u201343","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl 21","key":"62_CR11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1192\/S0007125000292465","volume":"163","author":"FM Quitkin","year":"1993","unstructured":"Quitkin FM, Stewart JW, McGrath PJ et al (1993) Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 163(Suppl 21):30\u201334","journal-title":"Br J Psychiatry"},{"key":"62_CR12","first-page":"45","volume":"28","author":"MV Rudorfer","year":"1992","unstructured":"Rudorfer MV (1992) Monoamine oxidase inhibitors: reversible and irreversible. Psychopharmacol Bull 28:45\u201357","journal-title":"Psychopharmacol Bull"},{"key":"62_CR13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archpsyc.1980.01780140053006","volume":"37","author":"DV Sheehan","year":"1980","unstructured":"Sheehan DV, Ballinger J, Jacobson G (1980) Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 37:51\u201359","journal-title":"Arch Gen Psychiatry"},{"key":"62_CR14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1192\/bjp.172.1.70","volume":"172","author":"FR Schneier","year":"1998","unstructured":"Schneier FR, Goetz D, Campeas R et al (1998) Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 172:70\u201377","journal-title":"Br J Psychiatry"},{"key":"62_CR15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0893-133X(94)00058-8","volume":"12","author":"ME Thase","year":"1995","unstructured":"Thase ME, Trivedi MH, Rush AJ (1995) MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12:185\u2013219","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 1","key":"62_CR16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0022-3956(88)90070-2","volume":"22","author":"P Tyrer","year":"1988","unstructured":"Tyrer P, Shawcross C (1988) Monoamine oxidase inhibitors in anxiety disorders. J Psychiatric Res 22(Suppl 1):87\u201398","journal-title":"J Psychiatric Res"},{"key":"62_CR17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004714-200206000-00008","volume":"22","author":"EH Uhlenhuth","year":"2002","unstructured":"Uhlenhuth EH, Warner TD, Matuzas W (2002) Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacology 22:275\u2013284","journal-title":"J Clin Psychopharmacology"},{"key":"62_CR18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1192\/bjp.161.3.353","volume":"161","author":"M Versiani","year":"1992","unstructured":"Versiani M, Nardi AE, Mundim FD (1992) Pharmacotherapy of social phobia: a controlled study with moclobiemide and phenelzine. Br J Psychiatry 161:353\u2013360","journal-title":"Br J Psychiatry"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-009-0062-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-009-0062-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-009-0062-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T18:20:13Z","timestamp":1559067613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-009-0062-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,21]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1007\/s00406-009-0062-9","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,21]]}}}